AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
AGIOS PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$34.90+3.58 (+11.43%)
Close on Oct 19, 2026
- Market cap
- $2.08B
- P/E (TTM)
- –
- Dividend yield
- –
AGIOS PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $54.03M | $36.50M | $26.82M | $11.74M | $0 | $0 | $59.85M | $13.84M | $0 | $0 | 100.0% | +48.0% |
| Milestone revenue | – | $0 | $0 | $2.50M | $0 | $0 | $10.54M | $7.22M | $1.94M | $0 | – | – |
| Collaboration revenue other | – | – | – | – | – | $3.57M | $8.26M | $12.67M | $0 | $0 | – | – |
| Collaboration revenue related party | – | – | – | – | – | $68.27M | $39.26M | $60.66M | $41.07M | $69.89M | – | – |
| On-going research and development services | – | – | – | – | – | $64.35M | $35.95M | $40.58M | $37.95M | – | – | – |
| Development activities | – | – | – | – | – | $0 | $0 | $1.34M | $0 | – | – | – |
| Licenses | – | – | – | – | – | $0 | $0 | $15.00M | $0 | – | – | – |
| Commercialization Activities | – | – | – | – | – | $3.93M | $3.30M | $3.74M | $2.95M | – | – | – |
| Committee participation | – | – | – | – | – | $0 | $0 | $0 | $167.00K | – | – | – |
| Other services | – | – | – | – | – | – | – | $200.00K | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Agios Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.